Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained AbbVie has moved quickly to deepen its immunology franchise, completing its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026, after first announcing the transaction during the second quarter.</li><li>The purchase is AbbVie’s largest bolt-on deal since 2019 and adds a portfolio of long-acting biologics targeting atopic dermatitis, respiratory conditions, and other immune-mediated diseases.</li><li>Management has framed Apogee as a strategic addition to a pipeline already anchored by Skyrizi and Rinvoq, with the aim of extending growth into the 2030s and beyond.</li></ul>

AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained AbbVie has moved quickly to deepen its immunology franchise, completing its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026, after first announcing the transaction during the second quarter.The purchase is AbbVie’s largest bolt-on deal since 2019 and adds a portfolio of long-acting biologics targeting atopic dermatitis, respiratory conditions, and other immune-mediated diseases.Management has framed Apogee as a strategic addition to a pipeline already anchored by Skyrizi and Rinvoq, with the aim of extending growth into the 2030s and beyond.

AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained!

<ul><li>AbbVie reported second quarter 2026 results that surpassed internal guidance, with adjusted earnings per share (EPS) reaching $3.65, exceeding the midpoint by $0.06.</li><li>Total net revenues approached $17 billion, reflecting a 10.2% operational growth and surpassing expectations by approximately $300 million.</li><li>The company’s major growth drivers included strong performances from immunology products Skyrizi and Rinvoq, as well as its neuroscience portfolio, each exhibiting growth rates above 20%.</li></ul>

AbbVie reported second quarter 2026 results that surpassed internal guidance, with adjusted earnings per share (EPS) reaching $3.65, exceeding the midpoint by $0.06.Total net revenues approached $17 billion, reflecting a 10.2% operational growth and surpassing expectations by approximately $300 million.The company’s major growth drivers included strong performances from immunology products Skyrizi and Rinvoq, as well as its neuroscience portfolio, each exhibiting growth rates above 20%.

AbbVie’s $600 Million Guidance Lift: Can Skyrizi & Rinvoq Keep Delivering?

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Hedge Fund News, Information and Data, Hedge Fund Alpha

Hedge Fund Alpha

Hedge Fund News, Information and Data

We focus on hedge funds with a bias towards emerging managers, specifically fundamental long-short managers. We are known for a lot of insights and exclusives on hedge fund letters, coverage of industry conferences, and interviews with investors and interesting service providers.

<ul><li>San Francisco-based Woodline Partners LP was formed in August 2018.</li><li>Its Form ADV lists Matthew Hooker, Karl Kroeker, and Michael Rockefeller as the firm’s principals.</li><li>As of June 30, 2026, the firm reported $32.35 billion across 1,011 disclosed long positions, according to its latest 13F filing.</li></ul>

San Francisco-based Woodline Partners LP was formed in August 2018.Its Form ADV lists Matthew Hooker, Karl Kroeker, and Michael Rockefeller as the firm’s principals.As of June 30, 2026, the firm reported $32.35 billion across 1,011 disclosed long positions, according to its latest 13F filing.

Woodline Partners Portfolio: Top Holdings (Q2 2026)

<ul><li>AbbVie Inc. is reportedly nearing an all-cash deal to acquire Apogee Therapeutics for roughly $10.9 billion, a price that would represent a steep premium for a biotech founded only in 2022.</li><li>On the surface, this looks like a bold bet on eczema, one of the most common and visible inflammatory skin conditions.</li><li>But the real story is broader than one disease.</li></ul>

AbbVie Inc. is reportedly nearing an all-cash deal to acquire Apogee Therapeutics for roughly $10.9 billion, a price that would represent a steep premium for a biotech founded only in 2022.On the surface, this looks like a bold bet on eczema, one of the most common and visible inflammatory skin conditions.But the real story is broader than one disease.

AbbVie’s $11 Billion Eczema Gamble Runs Deeper!

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbvie Inc (ABBV US)

AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained!

AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained AbbVie has moved quickly to deepen its immunology franchise, completing its...

Baptista Research

AbbVie’s $600 Million Guidance Lift: Can Skyrizi & Rinvoq Keep Delivering?

AbbVie reported second quarter 2026 results that surpassed internal guidance, with adjusted earnings per share (EPS) reaching $3.65, exceeding the...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Woodline Partners Portfolio: Top Holdings (Q2 2026)

San Francisco-based Woodline Partners LP was formed in August 2018.Its Form ADV lists Matthew Hooker, Karl Kroeker, and Michael Rockefeller as the...

Hedge Fund Alpha

AbbVie’s $11 Billion Eczema Gamble Runs Deeper!

AbbVie Inc. is reportedly nearing an all-cash deal to acquire Apogee Therapeutics for roughly $10.9 billion, a price that would represent a steep...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)